SynBioBeta Speaker
Paul Schnier
Lilly
AVP, Oncology
Paul Schnier is Associate Vice President of Multi-Omics in the Oncology Therapeutic Area at Lilly, where he leads the integration of advanced analytical and multi-omics platforms across discovery and development. His team enables data-driven decisions from target biology through clinical translation, with a focus on elucidating complex and low-abundance proteins, including the “dark immunopeptidome,” to inform mechanism of action and therapeutic strategy. Paul has extensive experience building multidisciplinary teams and applying innovative technologies to accelerate the development of next-generation medicines. He holds a Ph.D. in Physical Chemistry from UC Berkeley and has held scientific leadership roles at Amgen, Genentech, and UCSF.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Paul
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
